BIENAIME JEAN JACQUES bought KROS
August 17, 2026 · Form 4 insider transaction
BIENAIME JEAN JACQUES bought 1,000 shares of Keros Therapeutics, Inc. at $10.27 per share, a transaction worth $10.3K. The trade was recorded as open-market purchase under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.; The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.